A significant shift is underway in the landscape of small-molecule drug discovery, as a new collaborative platform seeks to revolutionize…
Read More
WTWH Media Rebrands to Arrowfly, Signaling Strategic Evolution in B2B Information and Events Landscape
Cleveland-based WTWH Media, a prominent and diversified entity within the business-to-business (B2B) media and events sector, officially announced its corporate…
Read More
Blazing new paths for biotech
For the past several years, success has grown more elusive for American biotech firms, navigating a dramatically altered landscape that…
Read More
Boehringer Ingelheim eyes MASH as the next front for survodutide, a GLP-1/glucagon receptor dual agonist
For decades, metabolic dysfunction-associated steatohepatitis (MASH), a more serious inflammatory form of fatty liver disease, remained a largely overlooked condition,…
Read More
American Diabetes Association Conference: Groundbreaking GLP-1 Discoveries Eclipsed by Scientific Freedom Protest
The annual scientific sessions of the American Diabetes Association (ADA) this week served as a dual stage: a vibrant forum…
Read More
CEPI Fast-Tracks Three Ebola Vaccine Candidates from IAVI, Moderna, and Oxford Amidst Bundibugyo Outbreak in DRC and Uganda
The Coalition for Epidemic Preparedness Innovations (CEPI) has announced the urgent fast-tracking of three investigational vaccine candidates aimed at combating…
Read More
J&J Positions Spravato Remission Data at Forefront of Treatment-Resistant Depression Growth Strategy
Johnson & Johnson (J&J) is intensifying its marketing efforts for Spravato (esketamine) by spotlighting compelling remission rate data for treatment-resistant…
Read More
How CTF is trying to rescue pharma’s shelved rare disease drugs
More than 5,000 potential treatments for rare diseases are currently languishing on pharmaceutical company shelves, representing a vast, untapped reservoir…
Read More
CNPV: A gamechanger for the pharma industry or simply more chaos?
The United States Food and Drug Administration (FDA) embarked on a pivotal initiative in June 2025 with the announcement of…
Read More
Calderasib’s real innovation: designed for combinability and potency
Merck has unveiled its investigational KRAS G12C inhibitor, calderasib, positioning it not merely as another potent molecule in a rapidly…
Read MoreYOU MAY HAVE MISSED
